Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The IMpower-132 trial for non small cell lung cancer

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US
The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )
29 Oct 2018

Keynote lecture: Mutation signatures and targeting the DNA damage response

Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK
Keynote lecture: Mutation signatures and targeting the DNA damage response ( Prof Thomas Helleday - Sheffield Cancer Centre, Sheffield, UK )
29 Oct 2018

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )
29 Oct 2018

Current clinical landscape for ALK non-small cell lung cancer patients

Dr Riyaz Shah and Dr Maurice Perol
Current clinical landscape for ALK  non-small cell lung cancer patients ( Dr Riyaz Shah and Dr Maurice Perol )
26 Oct 2018

Latest advances in treatment for ALK positive NSCLC

Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie,  Dr Lázaro Quintela )
26 Oct 2018

Highlights in early non-metastatic NSCLC and thoracic tumours

Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018

Combination strategies of immunotherapy in breast cancer

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2018

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC

Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018

Safety analysis of entrectinib for NTRK fusion tumours

Dr George D. Demetri - Harvard Cancer Center, Boston, USA
Safety analysis of entrectinib for NTRK fusion tumours ( Dr George D. Demetri - Harvard Cancer Center, Boston, USA )
26 Oct 2018

ASCEND-8: safety data of ceritinib with or without food in NSCLC

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )
26 Oct 2018

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )
26 Oct 2018